InvestorsHub Logo
Followers 24
Posts 1132
Boards Moderated 0
Alias Born 01/27/2021

Re: rosemountbomber post# 423856

Thursday, 05/02/2024 5:40:48 PM

Thursday, May 02, 2024 5:40:48 PM

Post# of 424599
I would think that the extension of the European patents to 2038 is the large enough window that Amarin needs for an eventual sale to a European pharmaceutical company. Now, it needs to secure Italy and France and get some price deals in places like Greece and Portugal under its belt. Then, it needs to show a trajectory of script growth in countries like England and Spain so a potential buyer can make projections about eventual sales. It would be nice if we could get something positive out of the BRAVE trial or the introduction of the Combo pill or something to make the company more appealing to a buyer. Then, it'll be important to unload the company next year sometime or in 2026 at the very latest so a buyer still has plenty of patent time to make money.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News